Abion's Q1 2026 Operating Loss of KRW 6.5B Continues... ABN501 Technology Export Contract Signed

Signed technology transfer agreement for 5 antibodies including ABN501 (CLDN3-targeting) (total USD 1,315M, upfront undisclosed, Jun 22, 2025)
ABN401 (Vabametkib) global phase 2 ongoing, orphan drug designation (MFDS, Aug 2025), BICR results secured (Jan 2026)
Consolidated revenue KRW 0.57B (R&D service 98.4%), operating loss KRW 6.54B, net loss KRW 6.58B
Consolidated cash & cash equiv. KRW 10.1B, short-term financial instruments KRW 8.0B, total borrowings KRW 7.05B, convertible bonds KRW 1.78B
Consolidated equity KRW 61.9B, liabilities KRW 11.9B, deficit KRW 257.9B
US patent lawsuit by Ocimum Biosolutions (unrelated to main pipeline, ongoing)